4-isopropoxy-2-methoxybenzaldehyde | 1079650-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-isopropoxy-2-methoxybenzaldehyde
• 英文别名: 2-methoxy-4-propan-2-yloxybenzaldehyde
• CAS: 1079650-39-7
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: DSBQLOIOODISLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE<br/>[FR] INHIBITEURS DE LA CYSTATHIONINE BÊTA SYNTHASE UTILISABLES EN VUE DE LA RÉDUCTION DE LA SURPRODUCTION NEUROTOXIQUE DE SULFURE D'HYDROGÈNE ENDOGÈNE
  申请人：FOND JEROME LEJEUNE

  公开号：WO2013068592A1

  公开（公告）日：2013-05-16

  The invention is directed to inhibitors of cystathionine beta synthase which, among other biochemical effects, allow reduction of the neurotoxic overproduction of endogenous hydrogen sulphide. These compounds and pharmaceutical compositions containing them are useful for the prevention and treatment of cognitive disorders such as cognitive disorders in Down syndrome. The invention also relates to methods for preventing or treating cognitive disorders including cognitive disorders in Down Syndrome.

  本发明涉及胱硫醚β合酶抑制剂，除其他生化作用外，还允许减少内源性硫化氢的神经毒性过度产生。这些化合物以及含有它们的药物组合物对于预防治疗认知障碍，如下氏综合症中的认知障碍等是有用的。本发明还涉及用于预防或治疗认知障碍的方法，包括下氏综合症中的认知障碍。
• Therapeutic Compounds 570
  申请人：Bayrakdarian Malken

  公开号：US20090099195A1

  公开（公告）日：2009-04-16

  Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , R 3 , R 4 , and R 5 and are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物或其药学上可接受的盐：其中R1、R2、R3、R4和R5如规范中所定义，以及制备包括这些化合物的盐和药物组合物。它们在治疗中有用，特别是在疼痛管理方面。
• NOVEL PYRAZOLE DERIVATIVE
  申请人：Sugimoto Hachiro

  公开号：US20140088029A1

  公开（公告）日：2014-03-27

  Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar 1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar 2 represents a 1H-indol-6-yl group etc.] or a salt thereof.

  提供了一种治疗阿尔茨海默病的新型治疗手段。具体而言，提供了一种由以下通式（I）表示的化合物：[其中Ar1代表2-甲氧基-4-(2-吡啶甲氧基)苯基等，Ar2代表1H-吲哚-6-基等]或其盐。
• EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
  申请人：Joint Stock Company "Biocad"

  公开号：EP3693365A1

  公开（公告）日：2020-08-12

  The present invention relates to novel compounds of formula I, or pharmaceutically acceptable salts, solvates or stereoisomers thereof, also to a pharmaceutical composition, a method for inhibiting biological activity of epidermal growth factor receptor (EGFR), a method for treating diseases or disorders mediated by the activation of EGFR and use of the present compounds or the present pharmaceutical composition for the treatment of a disease or disorder mediated by the activation of EGFR.

  本发明涉及式 I 的新型化合物、 或其药学上可接受的盐、溶解物或立体异构体，还涉及一种药物组合物、一种抑制表皮生长因子受体（EGFR）生物活性的方法、一种治疗由 EGFR 活化介导的疾病或紊乱的方法，以及使用本发明化合物或本发明药物组合物治疗由 EGFR 活化介导的疾病或紊乱。
• PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：AstraZeneca AB

  公开号：EP2155751A1

  公开（公告）日：2010-02-24